Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - neostigmine metilsulfate; glycopyrronium bromide - solution for injection - 2.5mg/1ml ; 500microgram/1ml

Marekani - Kiingereza - NLM (National Library of Medicine)

bryant ranch prepack - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 2 mg - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. glycopyrrolate tablet, usp are contraindicated in those patients with a hypersensitivity to glycopyrrolate. since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - glycopyrronium bromide - solution for injection - 200 microgram/ml

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

sintetica ireland limited - glycopyrronium bromide; neostigmine metilsulfate - solution for injection - 0.5 mg/ml + 2.5 milligram(s)/millilitre - glycopyrronium bromide

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

sintetica gmbh - glycopyrronium bromide; neostigmine metilsulfate - solution for injection - glycopyrronium bromide

Marekani - Kiingereza - NLM (National Library of Medicine)

par formulations private limited - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg - glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1- dimethylpyrrolidinium bromide. its empirical formula is c19 h28 brno3 , its molecular weight is 398.33, and its structural formula is: each 1 mg tablet contains: glycopyrrolate, usp ................1 mg each 2 mg tablet contains: glycopyrrolate, usp ................2 mg inactive ingredients: dibasic calcium phosphate, lactose, magnesium stearate, povidone, sodium starch glycolate.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

grand medical pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 160 microgram; glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - zimbus breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Marekani - Kiingereza - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). glycopyrrolate oral solution is contraindicated in: • patients with medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis). • patients taking solid oral dosage forms of potassium chloride. the passage of potassium chloride tablets through the gastrointestinal (gi) tract may be arrested or delayed with coadministration of glycopyrrolate oral solution. risk summary there are no available data in pregnant women for glycopyrrolate to inform decisions concerning any drug-associated risks. in pregnant rats, daily oral administration of glycopyrrolate during organogenesis at dose exposures 2.5 to 113 times the exp

Marekani - Kiingereza - NLM (National Library of Medicine)

appco pharma llcc - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg

Marekani - Kiingereza - NLM (National Library of Medicine)

avera mckennan hospital - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg